Connect Biopharma starts Phase 2 COPD study of rademikibart, topline data expected 1H 2026

Connect Biopharma Holdings Ltd

Phase 2 Seabreeze STAT COPD study initiated after FDA agreement on final protocol.
Study evaluates single-dose rademikibart vs placebo as adjunct to standard of care for acute COPD exacerbations.
Approximately 160 participants with type 2 inflammation (eosinophils ≥300 cells/μL) will be enrolled.
Primary endpoint: treatment failure rate over 28 days; topline data expected in first half of 2026.
Post-hoc analysis of prior Phase 2b asthma data in COPD-like patients to be presented at ATS 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.